Biosynthesis of PGD2 in Vivo (Niacin)
| Tracking Information | |
|---|---|
| First Received Date ICMJE | December 16, 2010 |
| Last Updated Date | May 14, 2013 |
| Start Date ICMJE | July 2007 |
| Primary Completion Date | January 2012 (final data collection date for primary outcome measure) |
| Current Primary Outcome Measures ICMJE |
Area under the urinary prostaglandins concentration versus time curve (AUC) in response to niacin and aspirin [ Time Frame: -2-0, 0-2, 2-4, 4-6, 6-12 and 12-24 hours pre or post niacin ] [ Designated as safety issue: No ] Area under the urinary prostaglandins concentration versus time curve (AUC) in response to niacin with or without pretreatment of aspirin will be studied. Area under the urinary prostaglandins concentration versus time curve (AUC) in response to aspirin will also be studied. |
| Original Primary Outcome Measures ICMJE | Same as current |
| Change History | Complete list of historical versions of study NCT01275300 on ClinicalTrials.gov Archive Site |
| Current Secondary Outcome Measures ICMJE |
Area under the flushing response versus time curve (AUC) in response to niacin [ Time Frame: 5 mins before niacin to 6 hours after niacin administertion (continuously) ] [ Designated as safety issue: No ] Area under the flushing response versus time curve (AUC) in response to niacin with or without pretreatment of aspirin will be studied. |
| Original Secondary Outcome Measures ICMJE |
Area under the flushing response versus time curve (AUC) in response to niacin [ Time Frame: 5 mins before niacin to 6 hours after niacin administertion (continuesly) ] [ Designated as safety issue: No ] Area under the flushing response versus time curve (AUC) in response to niacin with or without pretreatment of aspirin will be studied. |
| Current Other Outcome Measures ICMJE | Not Provided |
| Original Other Outcome Measures ICMJE | Not Provided |
| Descriptive Information | |
| Brief Title ICMJE | Biosynthesis of PGD2 in Vivo |
| Official Title ICMJE | A Pilot Study to Measure Plasma and Urinary Prostaglandin D2 Metabolites Evoked by Niacin |
| Brief Summary | We would like to see if aspirin could block niacin-induced flushing by analyzing blood and urine after taking aspirin. Phase I: 5 days of 81 mg aspirin/placebo followed by 600 mg Niacin, 2 week washout and 5 days taking the alternate. The order in which this is given will be randomized or assigned by chance. Phase II: One study week consisting of 5 days of taking 81 mg Aspirin, taken once daily, followed by a single dose of 600 mg Niacin on day 6. Phase III: 5 days taking 81 mg Aspirin/placebo, 10 day washout in between. Phase IV: Use of extended release niacin instead of instant release. Phase V: A Celebrex study is necessary to explore the contribution of Cox-2 to niacin induced flushing. |
| Detailed Description | The purpose of this study is to look at the roles of various blood cells and their contributions of different prostaglandins. The intention is that by better understanding these prostaglandins and various metabolites, it will provide insights into their roles in the cardiovascular system. Prostaglandins and metabolites are naturally occurring substances found in the blood and urine which can act as markers which can be quantified and studied as we will be doing in this study. Flushing response to niacin will also be assessed by laser doppler measuring blood flow of the facial skin. Untransformed and transformed data will be subjected to exploratory analysis of variance appropriated for a three factor design with one two period crossover factor and two non-repeated factors. Additionally, volunteer's test(s) for paired observations will characterize the magnitude of the niacin effect on the response variables within selected time points. |
| Study Type ICMJE | Interventional |
| Study Phase | Phase 4 |
| Study Design ICMJE | Allocation: Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention |
| Condition ICMJE | Healthy Volunteer |
| Intervention ICMJE |
|
| Study Arm (s) |
|
| Publications * | Not Provided |
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
| Recruitment Information | |
| Recruitment Status ICMJE | Completed |
| Enrollment ICMJE | 22 |
| Completion Date | January 2012 |
| Primary Completion Date | January 2012 (final data collection date for primary outcome measure) |
| Eligibility Criteria ICMJE | Inclusion Criteria: age between 18-70
Exclusion Criteria:
|
| Gender | Both |
| Ages | 18 Years to 70 Years |
| Accepts Healthy Volunteers | Yes |
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
| Location Countries ICMJE | United States |
| Administrative Information | |
| NCT Number ICMJE | NCT01275300 |
| Other Study ID Numbers ICMJE | 806115 - FitzGerald, MD, American Heart Association |
| Has Data Monitoring Committee | Yes |
| Responsible Party | University of Pennsylvania |
| Study Sponsor ICMJE | University of Pennsylvania |
| Collaborators ICMJE | American Heart Association |
| Investigators ICMJE | Not Provided |
| Information Provided By | University of Pennsylvania |
| Verification Date | March 2012 |
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|